INFI - Infinity Pharmaceuticals GAAP EPS of -$0.53 in-line revenue of $1.86M beats by $0.16M
Infinity Pharmaceuticals press release (NASDAQ:INFI): FY GAAP EPS of -$0.53 in-line. Revenue of $1.86M (+8.8% Y/Y) beats by $0.16M. Total cash, cash equivalents and available-for-sale securities of $80.7 million, compared to $34.1 million at December 31, 2020. Outlook 2022: Net Loss: Infinity expects net loss for 2022 to range from $45 million to $55 million; Cash and Investments: Infinity expects to end 2022 with a year-end cash, cash equivalents and available for sale securities balance ranging from $25 million to $35 million.
For further details see:
Infinity Pharmaceuticals GAAP EPS of -$0.53 in-line, revenue of $1.86M beats by $0.16M